Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer

Access Activity

Overview / Abstract:

This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. Start the activity now.


An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Though new screening procedures have identified more lung cancers at an earlier stage, most patients are still diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Chemoimmunotherapy has significantly improved the overall survival of patients compared with chemotherapy alone, but challenges remain in its optimal use (Tuminello et al, 2022). This activity will help update learners regarding this rapidly changing field. Ticiana Leal, MD, and Beth Sandy, MSN, CRNP, will analyze the latest guidance on patient selection, efficacy, safety, and supportive care strategies for non–small cell lung cancer immunotherapy.


Oncologists, pulmonologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with NSCLC.


Upon completion of this activity, participants should be able to
Identify patient selection criteria for immunotherapy in advanced NSCLC
Evaluate emerging efficacy and safety data on immunotherapy-based strategies for advanced NSCLC without driver mutations
Assess supportive care plans to control immune-mediated adverse events and optimize survivorship in patients with advanced NSCLC


Apr 05, 2023


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.25 CME | 1.25 NCPD | MOC | ILNA



Presenters / Authors / Faculty

Ticiana Leal, MD (Chairperson)
Associate Professor
Director, Thoracic Medical Oncology Program
Winship Cancer Institite
Emory University

Beth Sandy, MSN, CRNP
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Pulmonary Medicine / COPD

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck.

Keywords / Search Terms

i3 Health i3 Health, NSCLC, Non-Small Cell Lung Cancer, Pulmonology, Oncology, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME Free CE CME Free CE CME Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map